Generate Biomedicines, Inc.
GENBDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How GENB's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GB-0895 | Phase 3 | Severe Asthma | - | - |
Frequently asked questions
What is in Generate Biomedicines, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Generate Biomedicines, Inc.'s (GENB) pipeline across Phase 3. Its lead program is GB-0895 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Generate Biomedicines, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Generate Biomedicines, Inc. (GENB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GENB biotech catalysts?→
Add GENB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Generate Biomedicines, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.